Status:
COMPLETED
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Telangiectasia, Hereditary Hemorrhagic
Rendu Osler Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hereditary hemorrhagic telangiectasia (HHT) is linked to a dysregulation of angiogenesis leading to the formation of arteriovenous malformations (AVM): cutaneo-mucous telangiectasia and visceral shunt...
Eligibility Criteria
Inclusion
- Patient monitored for a clinically confirmed Rendu-Osler disease and / or confirmed by molecular biology, seen for an initial assessment or for a reassessment of PAVM (after treatment or without treatment)
- Patient who agreed to participate in the study and signed the written informed consent
- Patient affiliated to a social security scheme or similar
Exclusion
- Women who are pregnant, nursing (lactating) or at risk of pregnancy (verified by a urine test before performing the scanner)
- Patient who is protected adults under the terms of the law (French Public Health Code).
- Patient who has not or poorly understand French
Key Trial Info
Start Date :
November 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2021
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04108052
Start Date
November 28 2019
End Date
May 28 2021
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon - Hopital Louis Pradel
Bron, France, 69500